| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |